Protocol for antibody-dependent cellular phagocytosis assay with controlled IgG concentrations in tested samples Authors: Russell St. Germain, Anton M. Sholukh Published: 2026 ABSTRACT SummaryHere, we present a protocol to equalize antibody concentrations between samples to focus analysis on IgG properties rather than phagocytosis driven by antibody concentration. We describe steps for quantitating antigen-specific IgG in serum using a suitable binding assay, diluting samples to equalize IgG concentration, and using the antibody-dependent cellular phagocytosis (ADCP) assay. We then detail procedures for measuring differences in antibody properties between experimental groups by running diluted samples in the ADCP assay or other effector function assays.For complete details on the use and execution of this protocol, please refer to St. Germain et al.1 Before you begin The purpose of this protocol is to measure serum concentration of antigen-specific IgG and equalize it between different samples for the following antibody effector function assay. This allows exclusion of effect of IgG concentration on the effector function assay readout. Serum samples must be prepared and treated according to the appropriate safety guidelines including heat-inactivation, sterility and biosafety level. Appropriate institutional permissions should be obtained prior to sample collection and/or analysis. Innovation We introduce a normalization-first workflow for serum Antibody-Dependent Cellular Phagocytosis (ADCP) that removes a major, underappreciated source of bias in Fc-effector profiling. Standard ADCP protocols typically apply a uniform serum dilution, causing samples with higher baseline antigen-specific IgG concentrations to appear more active thus obscuring qualitative differences in antigen-specific IgG that affect effector functions. Our approach inserts a quantitative immunoassay step prior to ADCP to measure antigen-specific IgG concentration and then equalize samples to the same antigen-specific IgG input. We implement this using a bead-based Multiplex Binding Antigen Assay (MBAA) that reports antigen-specific IgG in absolute units (μg/mL), enabling precise normalization across cohorts and timepoints. By holding antigen-specific IgG concentration constant, downstream ADCP readouts become interpretable as a function of IgG quality—epitope specificity, subclass distribution, and Fc glycosylation—rather than dominated by antibody abundance. This improves comparability and rigor in identifying ADCP as a correlate of protection. This approach can be used to measure other antibody effector functions. Institutional permissions Informed consent was obtained from all human subjects, including blood donors, involved in the study. Plasma samples from SARS-CoV-2 seropositive, vaccinated individuals were obtained from Fred Hutchinson Cancer Center (FHCC) repository assembled from a COVID-19 seroepidemiology study conducted in a single county in the western US, FHCRC IRB#10453 and from University of Washington repository assembled from Seattle-area participants that were recruited for potential donation of single-donor plasma units (ClinicalTrials.gov: NCT04338360), and plasma for manufacture of a pooled anti–SARS-CoV-2 product (NCT04344977). Plasma from seronegative COVID vaccine recipients was obtained from either the same studies or from healthy volunteers at FHCRC (approved by the FHCRC Institutional Review Board, IRB#3612). This assay can be used for the analyses of human subject samples such as plasma or serum therefore appropriate approval should be acquired from Institution Review Board (IRB) for the use of human subject samples prior sample analysis. MagPlex microsphere conjugation protocol for multiplex binding antibody assay Timing: 4.5 h 1.Vortex MagPlex COOH microspheres and transfer an aliquot into a microcentrifuge tube. One MBAA 96-well plate requires 105 microspheres of each region.2.If more than one antigen is being conjugated, repeat procedure with different MagPlex microsphere region. CRITICAL: MagPlex microspheres are light sensitive. Minimize exposure to light by covering tubes in aluminum foil for all incubation steps. 3.Wash microspheres using BCP Activation buffer 3 times.a.Place microcentrifuge tube(s) on magnetic rack and incubate for 2 min protected from light.b.Remove buffer carefully using transfer 3 mL pipette (use one pipette per microsphere region), then resuspend microsphere in 500 mL activation buffer.c.Vortex tube(s) for 10 seconds and sonicate for another 10 seconds. Briefly spin in table-top centrifuge, then place tube(s) back on magnetic rack. CRITICAL: Do not use the same transfer pipette for different microsphere regions to prevent cross-contamination between different antigens in multiplex assay. Note: Magnetic microspheres sometimes are not entirely drawn to magnet and remain in solution. This can be seen as clumps floating in solution or a film on the surface. If this happens, vortex and sonicate beads for 30 s, then place back onto magnetic rack for 2 min. 4.Dissolve N-hydroxysuccinimide (NHS) in 40 μL/vial of BCP Activation buffer.5.Dissolve 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) in 250 μL/vial of BCP Activation buffer.6.After last wash, resuspend microspheres in 450 μL BCP Activation buffer. Add 50 μL NHS and 50 μL EDC.7.Incubate for 20 min at room temperature on rotator protected from light. Note: For incubations, wrap tubes in aluminum foil to protect from light. Incubate tubes on tabletop rotator to keep beads from settling in solution. 8.Wash microspheres 3 times using BCP Activation buffer.9.After last wash, resuspend microspheres in appropriate volume of BCP Activation buffer, then add antigen to reach a final volume of 500 μL.10.Incubate for 2 h at room temperature. Note: Amount of added antigen is calculated based on the general ratio of 1 μg antigen per 2.5 × 105 microspheres. The actual ratio for any new antigen should be established in a titration experiment. 11.Wash microspheres 3 times using BCP Wash buffer.12.Resuspend at a concentration of 1 × 107 microspheres per mL. Label and store at +4°C no longer than 1 month. Note: Conjugation of different antigens can be performed in parallel. Timing: 4.5 h 1.Vortex MagPlex COOH microspheres and transfer an aliquot into a microcentrifuge tube. One MBAA 96-well plate requires 105 microspheres of each region. Vortex MagPlex COOH microspheres and transfer an aliquot into a microcentrifuge tube. One MBAA 96-well plate requires 105 microspheres of each region. 2.If more than one antigen is being conjugated, repeat procedure with different MagPlex microsphere region. If more than one antigen is being conjugated, repeat procedure with different MagPlex microsphere region. CRITICAL: MagPlex microspheres are light sensitive. Minimize exposure to light by covering tubes in aluminum foil for all incubation steps. 3.Wash microspheres using BCP Activation buffer 3 times.a.Place microcentrifuge tube(s) on magnetic rack and incubate for 2 min protected from light.b.Remove buffer carefully using transfer 3 mL pipette (use one pipette per microsphere region), then resuspend microsphere in 500 mL activation buffer.c.Vortex tube(s) for 10 seconds and sonicate for another 10 seconds. Briefly spin in table-top centrifuge, then place tube(s) back on magnetic rack. Wash microspheres using BCP Activation buffer 3 times.a.Place microcentrifuge tube(s) on magnetic rack and incubate for 2 min protected from light.b.Remove buffer carefully using transfer 3 mL pipette (use one pipette per microsphere region), then resuspend microsphere in 500 mL activation buffer.c.Vortex tube(s) for 10 seconds and sonicate for another 10 seconds. Briefly spin in table-top centrifuge, then place tube(s) back on magnetic rack. a.Place microcentrifuge tube(s) on magnetic rack and incubate for 2 min protected from light. Place microcentrifuge tube(s) on magnetic rack and incubate for 2 min protected from light. b.Remove buffer carefully using transfer 3 mL pipette (use one pipette per microsphere region), then resuspend microsphere in 500 mL activation buffer. Remove buffer carefully using transfer 3 mL pipette (use one pipette per microsphere region), then resuspend microsphere in 500 mL activation buffer. c.Vortex tube(s) for 10 seconds and sonicate for another 10 seconds. Briefly spin in table-top centrifuge, then place tube(s) back on magnetic rack. Vortex tube(s) for 10 seconds and sonicate for another 10 seconds. Briefly spin in table-top centrifuge, then place tube(s) back on magnetic rack. CRITICAL: Do not use the same transfer pipette for different microsphere regions to prevent cross-contamination between different antigens in multiplex assay. Note: Magnetic microspheres sometimes are not entirely drawn to magnet and remain in solution. This can be seen as clumps floating in solution or a film on the surface. If this happens, vortex and sonicate beads for 30 s, then place back onto magnetic rack for 2 min. 4.Dissolve N-hydroxysuccinimide (NHS) in 40 μL/vial of BCP Activation buffer. Dissolve N-hydroxysuccinimide (NHS) in 40 μL/vial of BCP Activation buffer. 5.Dissolve 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) in 250 μL/vial of BCP Activation buffer. Dissolve 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) in 250 μL/vial of BCP Activation buffer. 6.After last wash, resuspend microspheres in 450 μL BCP Activation buffer. Add 50 μL NHS and 50 μL EDC. After last wash, resuspend microspheres in 450 μL BCP Activation buffer. Add 50 μL NHS and 50 μL EDC. 7.Incubate for 20 min at room temperature on rotator protected from light. Incubate for 20 min at room temperature on rotator protected from light. Note: For incubations, wrap tubes in aluminum foil to protect from light. Incubate tubes on tabletop rotator to keep beads from settling in solution. 8.Wash microspheres 3 times using BCP Activation buffer. Wash microspheres 3 times using BCP Activation buffer. 9.After last wash, resuspend microspheres in appropriate volume of BCP Activation buffer, then add antigen to reach a final volume of 500 μL. After last wash, resuspend microspheres in appropriate volume of BCP Activation buffer, then add antigen to reach a final volume of 500 μL. 10.Incubate for 2 h at room temperature. Incubate for 2 h at room temperature. Note: Amount of added antigen is calculated based on the general ratio of 1 μg antigen per 2.5 × 105 microspheres. The actual ratio for any new antigen should be established in a titration experiment. 11.Wash microspheres 3 times using BCP Wash buffer. Wash microspheres 3 times using BCP Wash buffer. 12.Resuspend at a concentration of 1 × 107 microspheres per mL. Label and store at +4°C no longer than 1 month. Resuspend at a concentration of 1 × 107 microspheres per mL. Label and store at +4°C no longer than 1 month. Note: Conjugation of different antigens can be performed in parallel. Preparation of IgG concentration standard Timing: 4 h 13.Mix all microsphere regions that are used in the panel together in equal parts to a total of 2.5 × 106 microspheres. Exact number of microspheres per region will depend on size of panel.14.Activate beads with NHS and EDC as described above.15.To conjugate, use Anti-human IgG Fab-specific at 20 μg/mL in the final volume of 500 μL of pooled beads.16.Incubate for 2 h at room temperature.17.Wash microspheres 3 times using BCP Wash buffer.18.Resuspend at a concentration of 1 × 107 microspheres/mL. Label and store at +4°C no longer than 1 month. Note: Conjugation of Standard beads can be done in parallel with antigens. Timing: 4 h 13.Mix all microsphere regions that are used in the panel together in equal parts to a total of 2.5 × 106 microspheres. Exact number of microspheres per region will depend on size of panel. Mix all microsphere regions that are used in the panel together in equal parts to a total of 2.5 × 106 microspheres. Exact number of microspheres per region will depend on size of panel. 14.Activate beads with NHS and EDC as described above. Activate beads with NHS and EDC as described above. 15.To conjugate, use Anti-human IgG Fab-specific at 20 μg/mL in the final volume of 500 μL of pooled beads. To conjugate, use Anti-human IgG Fab-specific at 20 μg/mL in the final volume of 500 μL of pooled beads. 16.Incubate for 2 h at room temperature. Incubate for 2 h at room temperature. 17.Wash microspheres 3 times using BCP Wash buffer. Wash microspheres 3 times using BCP Wash buffer. 18.Resuspend at a concentration of 1 × 107 microspheres/mL. Label and store at +4°C no longer than 1 month. Resuspend at a concentration of 1 × 107 microspheres/mL. Label and store at +4°C no longer than 1 month. Note: Conjugation of Standard beads can be done in parallel with antigens. Biotinylation of antigen proteins Timing: 45 min 19.Mix antigen of choice with 0.1 mM sulfo-NHS-LC-biotin at a 5-fold molar excess of biotin to protein.20.Incubate at room temperature for 30 min.21.Remove excess biotin using Zeba spin desalting columns according to manufacturer protocol:a.Place column in a collection tube. Centrifuge at 1500 × g for 1 minute.b.Equilibrate column with PBS: add PBS and centrifuge 1500 × g for 1 minute, discard flowthrough. Repeat 2 times.c.Add protein-biotin mix to Zeba spin desalting column. Centrifuge at 1500 × g for 2 min. Collect flowthrough.22.Measure protein concentration using absorbance at 280 nm or other method suitable for the protein of interest. Timing: 45 min 19.Mix antigen of choice with 0.1 mM sulfo-NHS-LC-biotin at a 5-fold molar excess of biotin to protein. Mix antigen of choice with 0.1 mM sulfo-NHS-LC-biotin at a 5-fold molar excess of biotin to protein. 20.Incubate at room temperature for 30 min. Incubate at room temperature for 30 min. 21.Remove excess biotin using Zeba spin desalting columns according to manufacturer protocol:a.Place column in a collection tube. Centrifuge at 1500 × g for 1 minute.b.Equilibrate column with PBS: add PBS and centrifuge 1500 × g for 1 minute, discard flowthrough. Repeat 2 times.c.Add protein-biotin mix to Zeba spin desalting column. Centrifuge at 1500 × g for 2 min. Collect flowthrough. Remove excess biotin using Zeba spin desalting columns according to manufacturer protocol:a.Place column in a collection tube. Centrifuge at 1500 × g for 1 minute.b.Equilibrate column with PBS: add PBS and centrifuge 1500 × g for 1 minute, discard flowthrough. Repeat 2 times.c.Add protein-biotin mix to Zeba spin desalting column. Centrifuge at 1500 × g for 2 min. Collect flowthrough. a.Place column in a collection tube. Centrifuge at 1500 × g for 1 minute. Place column in a collection tube. Centrifuge at 1500 × g for 1 minute. b.Equilibrate column with PBS: add PBS and centrifuge 1500 × g for 1 minute, discard flowthrough. Repeat 2 times. Equilibrate column with PBS: add PBS and centrifuge 1500 × g for 1 minute, discard flowthrough. Repeat 2 times. c.Add protein-biotin mix to Zeba spin desalting column. Centrifuge at 1500 × g for 2 min. Collect flowthrough. Add protein-biotin mix to Zeba spin desalting column. Centrifuge at 1500 × g for 2 min. Collect flowthrough. 22.Measure protein concentration using absorbance at 280 nm or other method suitable for the protein of interest. Measure protein concentration using absorbance at 280 nm or other method suitable for the protein of interest. Key resources table REAGENT or RESOURCESOURCEIDENTIFIERAntibodiesAnti-human IgG Fc-PE, 1:500 dilutionSouthernBiotech2040-09Human IgG, 0.2 μg/mLSigma-Aldrich12511Anti-human IgG Fab-specific, 1 mg/mLSouthernBiotech2085-01Biological samplesSerum from vaccinated seropositive individualsFHCCIRB#10453Serum from Seattle-area seroepidemiology study participantsUniversity of WashingtonNCT04338360Pooled anti-SARS-CoV-2 serumUniversity of WashingtonNCT04344977Chemicals, peptides, and recombinant proteinsRPMI 1640Gibco11875-093Sodium pyruvateGibco11360-070Sodium bicarbonateGibco25080-094HEPESGibco15630-080PenStrepGibco15070-063Fetal bovine serum (FBS)HyCloneSH30071.03Phosphate-buffered solution (PBS)Gibco14190-144Tween-20Sigma-AldrichP7949-500MLSodium AzideMillipore SigmaS8032ParaformaldehydeBosterAR1068Sulfo-NHS-LC-biotinThermo ScientificA39257Sulfo-NHSThermo ScientificA39269EDCThermo Scientific77149Trypan Blue stainInvitrogenT10282Experimental models: Cell linesTHP-1 monocytesATCCTIB-202Software and algorithmsGraphPad PrismGraphPad Softwarehttps://www.graphpad.com/how-to-buy/FlowJoBD Bioscienceshttps://www.flowjo.com/flowjo/downloadBio-Plex ManagerBio-Radhttps://www.bio-rad.com/en-us/product/bio-plex-manager-software-standard-edition?ID=5846e84e-03a7-4599-a8ae-7ba5dd2c7684OtherZeba spin desalting columnThermo Scientific89882Bio-Plex Pro™ Flat Bottom PlatesBio-Rad171025001Blotting-grade blockerBio-Rad1706404Tissue Culture Plates, 96-well, U-bottomGenesee Scientific25-221NeutrAvidin-labeled microspheresInvitrogenF8776Bovine serum albuminSAFC BiosciencesB4287-100GBio-Plex Pro Magnetic COOH beadsBio-RadMC10027-01Bio-Plex 200 SystemBio-RadN/A REAGENT or RESOURCESOURCEIDENTIFIERAntibodiesAnti-human IgG Fc-PE, 1:500 dilutionSouthernBiotech2040-09Human IgG, 0.2 μg/mLSigma-Aldrich12511Anti-human IgG Fab-specific, 1 mg/mLSouthernBiotech2085-01Biological samplesSerum from vaccinated seropositive individualsFHCCIRB#10453Serum from Seattle-area seroepidemiology study participantsUniversity of WashingtonNCT04338360Pooled anti-SARS-CoV-2 serumUniversity of WashingtonNCT04344977Chemicals, peptides, and recombinant proteinsRPMI 1640Gibco11875-093Sodium pyruvateGibco11360-070Sodium bicarbonateGibco25080-094HEPESGibco15630-080PenStrepGibco15070-063Fetal bovine serum (FBS)HyCloneSH30071.03Phosphate-buffered solution (PBS)Gibco14190-144Tween-20Sigma-AldrichP7949-500MLSodium AzideMillipore SigmaS8032ParaformaldehydeBosterAR1068Sulfo-NHS-LC-biotinThermo ScientificA39257Sulfo-NHSThermo ScientificA39269EDCThermo Scientific77149Trypan Blue stainInvitrogenT10282Experimental models: Cell linesTHP-1 monocytesATCCTIB-202Software and algorithmsGraphPad PrismGraphPad Softwarehttps://www.graphpad.com/how-to-buy/FlowJoBD Bioscienceshttps://www.flowjo.com/flowjo/downloadBio-Plex ManagerBio-Radhttps://www.bio-rad.com/en-us/product/bio-plex-manager-software-standard-edition?ID=5846e84e-03a7-4599-a8ae-7ba5dd2c7684OtherZeba spin desalting columnThermo Scientific89882Bio-Plex Pro™ Flat Bottom PlatesBio-Rad171025001Blotting-grade blockerBio-Rad1706404Tissue Culture Plates, 96-well, U-bottomGenesee Scientific25-221NeutrAvidin-labeled microspheresInvitrogenF8776Bovine serum albuminSAFC BiosciencesB4287-100GBio-Plex Pro Magnetic COOH beadsBio-RadMC10027-01Bio-Plex 200 SystemBio-RadN/A Materials and equipment For our MBAA experiments, Bio-Rad Bio-Plex 200 system operated via Bio-Plex Manager v6.2 was used. Any Luminex-based instrument such as Luminex-200, xMAP IntelliFlex, FlexMap 3D can be used instead. For ADCP assays, we used BD FACSCanto flow cytometer operated via FACSDiva software v8.0. Any flow cytometer capable of measuring FITC fluorophore can be used instead.BCP Wash bufferReagentFinal concentrationAmountTween-20 (25%)0.05%0.4 mLNaN3 (10%)0.1%2 mLBovine serum albumin10 mg/mL2 gPBSN/A195.6 mLTotalN/A200 mL[Store at room temperature, maximum storage time of 1 month or prepare fresh per experiment].MBAA Block bufferReagentFinal concentrationAmountTween-20 (25%)0.1%0.8 mLBlotting-grade blocker50 mg/mL10 g10× PBS1×20 mLddH2ON/A170 mLTotalN/A200 mL[Store at +4°C, maximum storage time of 1 month or prepare fresh per experiment].MBAA Assay bufferReagentFinal concentrationAmountTween-20 (25%)0.1%2 mLBlotting-grade blocker10 mg/mL5 g10× PBS1×50 mLddH2ON/A443 mLTotalN/A500 mL[Store at +4°C, maximum storage time of 1 month or prepare fresh per experiment].MBAA Run bufferReagentFinal concentrationAmountTween-20 (25%)0.1%2 mLBovine serum albumin1 mg/mL0.5 g10× PBS1×50 mLddH2ON/A448 mLTotalN/A500 mL[Store at +4°C, maximum storage time of 1 month or prepare fresh per experiment].R10 cell mediaReagentFinal concentrationAmountSodium pyruvate (100 mM)1 mM5 mLSodium bicarbonate (7.5%)0.075%5 mLHEPES (1 M)10 mM5 mLFetal bovine serum10%50 mLPenStrepN/A5 mLRPMI 1640N/A430 mLTotalN/A500 mL[Store at +4°C, maximum storage time of 1 month or prepare fresh per experiment]. BCP Wash bufferReagentFinal concentrationAmountTween-20 (25%)0.05%0.4 mLNaN3 (10%)0.1%2 mLBovine serum albumin10 mg/mL2 gPBSN/A195.6 mLTotalN/A200 mL[Store at room temperature, maximum storage time of 1 month or prepare fresh per experiment]. BCP Wash buffer [Store at room temperature, maximum storage time of 1 month or prepare fresh per experiment]. MBAA Block bufferReagentFinal concentrationAmountTween-20 (25%)0.1%0.8 mLBlotting-grade blocker50 mg/mL10 g10× PBS1×20 mLddH2ON/A170 mLTotalN/A200 mL[Store at +4°C, maximum storage time of 1 month or prepare fresh per experiment]. MBAA Block buffer [Store at +4°C, maximum storage time of 1 month or prepare fresh per experiment]. MBAA Assay bufferReagentFinal concentrationAmountTween-20 (25%)0.1%2 mLBlotting-grade blocker10 mg/mL5 g10× PBS1×50 mLddH2ON/A443 mLTotalN/A500 mL[Store at +4°C, maximum storage time of 1 month or prepare fresh per experiment]. MBAA Assay buffer [Store at +4°C, maximum storage time of 1 month or prepare fresh per experiment]. MBAA Run bufferReagentFinal concentrationAmountTween-20 (25%)0.1%2 mLBovine serum albumin1 mg/mL0.5 g10× PBS1×50 mLddH2ON/A448 mLTotalN/A500 mL[Store at +4°C, maximum storage time of 1 month or prepare fresh per experiment]. MBAA Run buffer [Store at +4°C, maximum storage time of 1 month or prepare fresh per experiment]. R10 cell mediaReagentFinal concentrationAmountSodium pyruvate (100 mM)1 mM5 mLSodium bicarbonate (7.5%)0.075%5 mLHEPES (1 M)10 mM5 mLFetal bovine serum10%50 mLPenStrepN/A5 mLRPMI 1640N/A430 mLTotalN/A500 mL[Store at +4°C, maximum storage time of 1 month or prepare fresh per experiment]. R10 cell media [Store at +4°C, maximum storage time of 1 month or prepare fresh per experiment]. BCP activation buffer •0.1 M MES hydrate: add 3.905 g MES hydrate in 200 mL ddH2O. Adjust to pH 6.0.[Store at room temperature, maximum storage time of 1 month]. •0.1 M MES hydrate: add 3.905 g MES hydrate in 200 mL ddH2O. Adjust to pH 6.0.[Store at room temperature, maximum storage time of 1 month]. 0.1 M MES hydrate: add 3.905 g MES hydrate in 200 mL ddH2O. Adjust to pH 6.0.[Store at room temperature, maximum storage time of 1 month]. MBAA wash buffer •0.1% Tween-20: add 4 mL of 25% Tween-20 in 996 mL of 1× PBS.[Store at +4°C, maximum storage time of 1 month]. •0.1% Tween-20: add 4 mL of 25% Tween-20 in 996 mL of 1× PBS.[Store at +4°C, maximum storage time of 1 month]. 0.1% Tween-20: add 4 mL of 25% Tween-20 in 996 mL of 1× PBS.[Store at +4°C, maximum storage time of 1 month]. ADCP assay buffer •1% bovine serum albumin: Dissolve 2 g BSA in 200 mL 1× PBS.[Store at +4°C] Alternatives: We have not tested other buffer compositions but the used buffer components are common and as such these buffers can be easily prepared in any laboratory. •1% bovine serum albumin: Dissolve 2 g BSA in 200 mL 1× PBS.[Store at +4°C] 1% bovine serum albumin: Dissolve 2 g BSA in 200 mL 1× PBS.[Store at +4°C] Alternatives: We have not tested other buffer compositions but the used buffer components are common and as such these buffers can be easily prepared in any laboratory. Step-by-step method details Multiplex binding antibody assay Timing: 5.5 h Timing: 5.5 h This assay is for measurement of antigen-specific IgG concentration present in serum samples. Data will be used to adjust serum dilutions used in the ADCP assay.1.Calculate volume of microspheres needed for assay.Note: 1 well on 96-well plate will need 1000 beads of each region in the panel.a.Remove desired microspheres from +4°C.b.Vortex for 1 minute, then sonicate for 1 minute.2.Add 1 mL MBAA Block buffer to 1.5 mL microcentrifuge tube.3.Add 10 μL antigen microspheres to blocking buffer. In another tube, add 1 mL block buffer and 24 μL IgG standard microspheres.4.Set up incubation for 1 hour at room temperature on rotator.Note: Cover tubes in aluminum foil to protect beads from light.5.Proceed to preparing IgG standard and sample dilutions. Both standard IgG and experimental samples to be diluted in MBAA Assay buffer.6.Dilute standard human IgG to a concentration of 10 μg/mL in MBAA Assay buffer in microcentrifuge tube.7.In U-bottom Tissue Culture Plates, add 96 μL of Assay buffer to row A, columns 1–2 and 60 μL to rows B-H, columns 1–2. Add 98 μL of Assay buffer to row A, columns 3–12 and 60 μL to rows B-H. columns 3–12.8.Prepare IgG standard by adding 4 μL of prepared IgG solution to 96 μL Assay buffer in wells A1 and A2 and serially dilute them 3-fold for 8 dilutions total by transferring 30 μL in rows B-H. Discard 30 μL from row H.9.Prepare serum dilutions by adding 2 μL serum sample to 98 μL Assay buffer in row A.Note: Number of replicates for serum samples should be determined based on study.10.Serially dilute samples 3-fold for 8 dilutions total by transferring 30 μL across dilution series (rows A through H).a.For each step, mix well contents at least 5 times, then transfer 30 μL to next well in the series. Discard 30 μL from row H.11.Transfer 50 μL of prepared dilutions to new Bio-Plex Pro™ Flat Bottom Plates.12.After blocking, place tube with microspheres on magnetic rack and protect from light for 2 min.13.Carefully remove Block buffer from antigen microspheres using micropipette and resuspend in MBAA Assay buffer to obtain a concentration of 2 × 104 microspheres/mL. Resuspend IgG standard microspheres in 1 mL assay buffer.14.Add 50 μL antigen microsphere mix to wells containing 50 μL serum dilutions. Add 50 μL IgG standard microspheres to diluted IgG.15.Protect plate from light and incubate for 1 hour at room temperature on plate shaker set to 850 rpm.16.Wash microspheres using MBAA Wash buffer 3 times using magnetic plate rack.a.Place plate on magnetic plate separator and wait 2 min.b.Dump supernatant from plate. Blot plate on absorbent pad to remove residual droplets.c.Remove plate from separator and resuspend each well with 120 μL MBAA Wash buffer. Place plate on shaker for 5 seconds at 1000 rpm to resuspend microspheres.17.Dilute anti-human IgG-PE 1:500 in MBAA Assay buffer. Add 100 μL of this dilution to all wells of experiment plate.18.Protect plate from light and incubate for 1 hour at room temperature on plate shaker.19.Wash microspheres again using MBAA Wash buffer 3 times. Alternatively, automatic plate washer, such as Bio-Rad Bio-Plex Pro Wash Station or equivalent, can be used.20.Resuspend microspheres in 100 μL MBAA Run buffer using plate shaker set to 1000 rpm. Read plate on Bio-Plex 200 or any other Luminex-compatible instrument.Note: Plates can be read immediately or stored at +4°C on plate shaker set to 500 rpm for reading next day.21.Calculate concentration of antigen-specific IgG using calibration curve made with IgG standard (Figure 1).Figure 1Example standard curve for MBAA to quantify antigen-specific IgG(A) Binding curve for SARS-CoV-2 Spike antigen. Square symbols represent IgG standard concentrations and triangle symbols represent unknown serum concentrations at different serial dilutions.(B) Binding curve for SARS-CoV-2 RBD antigen.(C) Binding curve for tetanus toxoid antigen. This was used as positive control as most people have tetanus antibodies from vaccination.CRITICAL: When incubating beads during blocking and plates during primary and secondary incubations, protect from light by using opaque plates or wrapping plates in aluminum foil. Microspheres are light sensitive, and photo-bleaching will lead to poor results. 1.Calculate volume of microspheres needed for assay.Note: 1 well on 96-well plate will need 1000 beads of each region in the panel.a.Remove desired microspheres from +4°C.b.Vortex for 1 minute, then sonicate for 1 minute. Calculate volume of microspheres needed for assay.Note: 1 well on 96-well plate will need 1000 beads of each region in the panel.a.Remove desired microspheres from +4°C.b.Vortex for 1 minute, then sonicate for 1 minute. Note: 1 well on 96-well plate will need 1000 beads of each region in the panel. a.Remove desired microspheres from +4°C. Remove desired microspheres from +4°C. b.Vortex for 1 minute, then sonicate for 1 minute. Vortex for 1 minute, then sonicate for 1 minute. 2.Add 1 mL MBAA Block buffer to 1.5 mL microcentrifuge tube. Add 1 mL MBAA Block buffer to 1.5 mL microcentrifuge tube. 3.Add 10 μL antigen microspheres to blocking buffer. In another tube, add 1 mL block buffer and 24 μL IgG standard microspheres. Add 10 μL antigen microspheres to blocking buffer. In another tube, add 1 mL block buffer and 24 μL IgG standard microspheres. 4.Set up incubation for 1 hour at room temperature on rotator. Set up incubation for 1 hour at room temperature on rotator. Note: Cover tubes in aluminum foil to protect beads from light. 5.Proceed to preparing IgG standard and sample dilutions. Both standard IgG and experimental samples to be diluted in MBAA Assay buffer. Proceed to preparing IgG standard and sample dilutions. Both standard IgG and experimental samples to be diluted in MBAA Assay buffer. 6.Dilute standard human IgG to a concentration of 10 μg/mL in MBAA Assay buffer in microcentrifuge tube. Dilute standard human IgG to a concentration of 10 μg/mL in MBAA Assay buffer in microcentrifuge tube. 7.In U-bottom Tissue Culture Plates, add 96 μL of Assay buffer to row A, columns 1–2 and 60 μL to rows B-H, columns 1–2. Add 98 μL of Assay buffer to row A, columns 3–12 and 60 μL to rows B-H. columns 3–12. In U-bottom Tissue Culture Plates, add 96 μL of Assay buffer to row A, columns 1–2 and 60 μL to rows B-H, columns 1–2. Add 98 μL of Assay buffer to row A, columns 3–12 and 60 μL to rows B-H. columns 3–12. 8.Prepare IgG standard by adding 4 μL of prepared IgG solution to 96 μL Assay buffer in wells A1 and A2 and serially dilute them 3-fold for 8 dilutions total by transferring 30 μL in rows B-H. Discard 30 μL from row H. Prepare IgG standard by adding 4 μL of prepared IgG solution to 96 μL Assay buffer in wells A1 and A2 and serially dilute them 3-fold for 8 dilutions total by transferring 30 μL in rows B-H. Discard 30 μL from row H. 9.Prepare serum dilutions by adding 2 μL serum sample to 98 μL Assay buffer in row A. Prepare serum dilutions by adding 2 μL serum sample to 98 μL Assay buffer in row A. Note: Number of replicates for serum samples should be determined based on study. 10.Serially dilute samples 3-fold for 8 dilutions total by transferring 30 μL across dilution series (rows A through H).a.For each step, mix well contents at least 5 times, then transfer 30 μL to next well in the series. Discard 30 μL from row H. Serially dilute samples 3-fold for 8 dilutions total by transferring 30 μL across dilution series (rows A through H).a.For each step, mix well contents at least 5 times, then transfer 30 μL to next well in the series. Discard 30 μL from row H. a.For each step, mix well contents at least 5 times, then transfer 30 μL to next well in the series. Discard 30 μL from row H. For each step, mix well contents at least 5 times, then transfer 30 μL to next well in the series. Discard 30 μL from row H. 11.Transfer 50 μL of prepared dilutions to new Bio-Plex Pro™ Flat Bottom Plates. Transfer 50 μL of prepared dilutions to new Bio-Plex Pro™ Flat Bottom Plates. 12.After blocking, place tube with microspheres on magnetic rack and protect from light for 2 min. After blocking, place tube with microspheres on magnetic rack and protect from light for 2 min. 13.Carefully remove Block buffer from antigen microspheres using micropipette and resuspend in MBAA Assay buffer to obtain a concentration of 2 × 104 microspheres/mL. Resuspend IgG standard microspheres in 1 mL assay buffer. Carefully remove Block buffer from antigen microspheres using micropipette and resuspend in MBAA Assay buffer to obtain a concentration of 2 × 104 microspheres/mL. Resuspend IgG standard microspheres in 1 mL assay buffer. 14.Add 50 μL antigen microsphere mix to wells containing 50 μL serum dilutions. Add 50 μL IgG standard microspheres to diluted IgG. Add 50 μL antigen microsphere mix to wells containing 50 μL serum dilutions. Add 50 μL IgG standard microspheres to diluted IgG. 15.Protect plate from light and incubate for 1 hour at room temperature on plate shaker set to 850 rpm. Protect plate from light and incubate for 1 hour at room temperature on plate shaker set to 850 rpm. 16.Wash microspheres using MBAA Wash buffer 3 times using magnetic plate rack.a.Place plate on magnetic plate separator and wait 2 min.b.Dump supernatant from plate. Blot plate on absorbent pad to remove residual droplets.c.Remove plate from separator and resuspend each well with 120 μL MBAA Wash buffer. Place plate on shaker for 5 seconds at 1000 rpm to resuspend microspheres. Wash microspheres using MBAA Wash buffer 3 times using magnetic plate rack.a.Place plate on magnetic plate separator and wait 2 min.b.Dump supernatant from plate. Blot plate on absorbent pad to remove residual droplets.c.Remove plate from separator and resuspend each well with 120 μL MBAA Wash buffer. Place plate on shaker for 5 seconds at 1000 rpm to resuspend microspheres. a.Place plate on magnetic plate separator and wait 2 min. Place plate on magnetic plate separator and wait 2 min. b.Dump supernatant from plate. Blot plate on absorbent pad to remove residual droplets. Dump supernatant from plate. Blot plate on absorbent pad to remove residual droplets. c.Remove plate from separator and resuspend each well with 120 μL MBAA Wash buffer. Place plate on shaker for 5 seconds at 1000 rpm to resuspend microspheres. Remove plate from separator and resuspend each well with 120 μL MBAA Wash buffer. Place plate on shaker for 5 seconds at 1000 rpm to resuspend microspheres. 17.Dilute anti-human IgG-PE 1:500 in MBAA Assay buffer. Add 100 μL of this dilution to all wells of experiment plate. Dilute anti-human IgG-PE 1:500 in MBAA Assay buffer. Add 100 μL of this dilution to all wells of experiment plate. 18.Protect plate from light and incubate for 1 hour at room temperature on plate shaker. Protect plate from light and incubate for 1 hour at room temperature on plate shaker. 19.Wash microspheres again using MBAA Wash buffer 3 times. Alternatively, automatic plate washer, such as Bio-Rad Bio-Plex Pro Wash Station or equivalent, can be used. Wash microspheres again using MBAA Wash buffer 3 times. Alternatively, automatic plate washer, such as Bio-Rad Bio-Plex Pro Wash Station or equivalent, can be used. 20.Resuspend microspheres in 100 μL MBAA Run buffer using plate shaker set to 1000 rpm. Read plate on Bio-Plex 200 or any other Luminex-compatible instrument. Resuspend microspheres in 100 μL MBAA Run buffer using plate shaker set to 1000 rpm. Read plate on Bio-Plex 200 or any other Luminex-compatible instrument. Note: Plates can be read immediately or stored at +4°C on plate shaker set to 500 rpm for reading next day. 21.Calculate concentration of antigen-specific IgG using calibration curve made with IgG standard (Figure 1).Figure 1Example standard curve for MBAA to quantify antigen-specific IgG(A) Binding curve for SARS-CoV-2 Spike antigen. Square symbols represent IgG standard concentrations and triangle symbols represent unknown serum concentrations at different serial dilutions.(B) Binding curve for SARS-CoV-2 RBD antigen.(C) Binding curve for tetanus toxoid antigen. This was used as positive control as most people have tetanus antibodies from vaccination. Calculate concentration of antigen-specific IgG using calibration curve made with IgG standard (Figure 1).Figure 1Example standard curve for MBAA to quantify antigen-specific IgG(A) Binding curve for SARS-CoV-2 Spike antigen. Square symbols represent IgG standard concentrations and triangle symbols represent unknown serum concentrations at different serial dilutions.(B) Binding curve for SARS-CoV-2 RBD antigen.(C) Binding curve for tetanus toxoid antigen. This was used as positive control as most people have tetanus antibodies from vaccination. Example standard curve for MBAA to quantify antigen-specific IgG (A) Binding curve for SARS-CoV-2 Spike antigen. Square symbols represent IgG standard concentrations and triangle symbols represent unknown serum concentrations at different serial dilutions. (B) Binding curve for SARS-CoV-2 RBD antigen. (C) Binding curve for tetanus toxoid antigen. This was used as positive control as most people have tetanus antibodies from vaccination. CRITICAL: When incubating beads during blocking and plates during primary and secondary incubations, protect from light by using opaque plates or wrapping plates in aluminum foil. Microspheres are light sensitive, and photo-bleaching will lead to poor results. Antibody-dependent cellular phagocytosis assay Timing: 1 day Note: Before beginning assay, use antigen-specific IgG content measured in MBAA to calculate dilution needed to adjust serum samples to 200 ng/mL concentration of antigen-specific IgG. Timing: 1 day Note: Before beginning assay, use antigen-specific IgG content measured in MBAA to calculate dilution needed to adjust serum samples to 200 ng/mL concentration of antigen-specific IgG. Culture THP-1 cells for at least 10 days in R10 media at 37°C in the presence of 5% CO2 after thawing of cell stock. Keep cell density below 5 × 105 cells/mL to reduce assay variability.22.Mix NeutrAvidin® beads with biotinylated antigen at a ratio of 3.85 × 107 beads per 1 μg antigen in microcentrifuge tube. Dilute to reach final protein concentration of 10 μg/mL in 1× PBS.23.Cover tube in aluminum foil to protect from light. Incubate on rotator at +4°C for 3 h.24.After incubation, wash beads 3 times.a.Centrifuge bead-antigen mixture at 12,000 × g for 5 min.b.Carefully remove supernatant using micropipette. Resuspend beads in 500 μL ADCP assay buffer.c.After last wash, resuspend beads in ADCP assay buffer to reach final bead concentration of 2 × 104 beads/mL.25.In U-bottom Tissue Culture Plates, dilute samples in RPMI to a final antigen-specific IgG concentration of 200 ng/mL into rows A and E. Pipette 60 μL RPMI into rows B through D and F through H.Note: Number of replicates for serum samples should be determined based on study.Note: Final volume in rows A and E will be determined by IgG concentration of sample but needs to be above 60 μL for step 11.26.Serially dilute samples 4-fold for 4 dilutions total by transferring 20 μL across dilution series (rows A through D and E through F).a.For each step, mix well contents at least 5 times, then transfer 20 μL to next well in the series. Discard 20 μL from rows D and H.27.Move 50 μL of prepared dilutions to a new U-bottom Tissue Culture Plates.28.Add 50 μL washed beads at 2 × 104 beads/mL concentration to the 50 μL of sample dilutions.29.Protect plate from light and incubate at room temperature for 1 hour on plate shaker set to 850 rpm.Optional: For samples with concentration of antigen-specific IgG higher than 1 μg/mL, use a separate round-bottom plate to dilute these high IgG samples to 1 μg/mL as a step dilution.30.Spin plates at 1500 × g for 10 min to pellet beads.31.While plates are in centrifuge, prepare THP-1 cells. Count cell concentration and suspend cells to a concentration of 1 × 105 cells/mL.32.Carefully remove supernatant from plates. Resuspend beads in 200 μL of cells.33.Incubate at 37°C for 18 h.34.After incubation, spin plates at 300 × g for 5 min.35.Remove 100 μL supernatant from wells. Add 100 μL of 4% paraformaldehyde (PFA) to wells and resuspend cells using pipettor.36.Protect plate from light and incubate at room temperature for 15 min.37.Spin plates at 300 × g for 5 min.38.Carefully remove all supernatant from cells. Resuspend cells in 200 μL ADCP Assay buffer. Read plate in flow cytometer analyzing percentage of FITC+ cells.Note: Plates can be read immediately or stored at +4°C for up to one week before reading. 22.Mix NeutrAvidin® beads with biotinylated antigen at a ratio of 3.85 × 107 beads per 1 μg antigen in microcentrifuge tube. Dilute to reach final protein concentration of 10 μg/mL in 1× PBS. Mix NeutrAvidin® beads with biotinylated antigen at a ratio of 3.85 × 107 beads per 1 μg antigen in microcentrifuge tube. Dilute to reach final protein concentration of 10 μg/mL in 1× PBS. 23.Cover tube in aluminum foil to protect from light. Incubate on rotator at +4°C for 3 h. Cover tube in aluminum foil to protect from light. Incubate on rotator at +4°C for 3 h. 24.After incubation, wash beads 3 times.a.Centrifuge bead-antigen mixture at 12,000 × g for 5 min.b.Carefully remove supernatant using micropipette. Resuspend beads in 500 μL ADCP assay buffer.c.After last wash, resuspend beads in ADCP assay buffer to reach final bead concentration of 2 × 104 beads/mL. After incubation, wash beads 3 times.a.Centrifuge bead-antigen mixture at 12,000 × g for 5 min.b.Carefully remove supernatant using micropipette. Resuspend beads in 500 μL ADCP assay buffer.c.After last wash, resuspend beads in ADCP assay buffer to reach final bead concentration of 2 × 104 beads/mL. a.Centrifuge bead-antigen mixture at 12,000 × g for 5 min. Centrifuge bead-antigen mixture at 12,000 × g for 5 min. b.Carefully remove supernatant using micropipette. Resuspend beads in 500 μL ADCP assay buffer. Carefully remove supernatant using micropipette. Resuspend beads in 500 μL ADCP assay buffer. c.After last wash, resuspend beads in ADCP assay buffer to reach final bead concentration of 2 × 104 beads/mL. After last wash, resuspend beads in ADCP assay buffer to reach final bead concentration of 2 × 104 beads/mL. 25.In U-bottom Tissue Culture Plates, dilute samples in RPMI to a final antigen-specific IgG concentration of 200 ng/mL into rows A and E. Pipette 60 μL RPMI into rows B through D and F through H. In U-bottom Tissue Culture Plates, dilute samples in RPMI to a final antigen-specific IgG concentration of 200 ng/mL into rows A and E. Pipette 60 μL RPMI into rows B through D and F through H. Note: Number of replicates for serum samples should be determined based on study. Note: Final volume in rows A and E will be determined by IgG concentration of sample but needs to be above 60 μL for step 11. 26.Serially dilute samples 4-fold for 4 dilutions total by transferring 20 μL across dilution series (rows A through D and E through F).a.For each step, mix well contents at least 5 times, then transfer 20 μL to next well in the series. Discard 20 μL from rows D and H. Serially dilute samples 4-fold for 4 dilutions total by transferring 20 μL across dilution series (rows A through D and E through F).a.For each step, mix well contents at least 5 times, then transfer 20 μL to next well in the series. Discard 20 μL from rows D and H. a.For each step, mix well contents at least 5 times, then transfer 20 μL to next well in the series. Discard 20 μL from rows D and H. For each step, mix well contents at least 5 times, then transfer 20 μL to next well in the series. Discard 20 μL from rows D and H. 27.Move 50 μL of prepared dilutions to a new U-bottom Tissue Culture Plates. Move 50 μL of prepared dilutions to a new U-bottom Tissue Culture Plates. 28.Add 50 μL washed beads at 2 × 104 beads/mL concentration to the 50 μL of sample dilutions. Add 50 μL washed beads at 2 × 104 beads/mL concentration to the 50 μL of sample dilutions. 29.Protect plate from light and incubate at room temperature for 1 hour on plate shaker set to 850 rpm. Protect plate from light and incubate at room temperature for 1 hour on plate shaker set to 850 rpm. Optional: For samples with concentration of antigen-specific IgG higher than 1 μg/mL, use a separate round-bottom plate to dilute these high IgG samples to 1 μg/mL as a step dilution. 30.Spin plates at 1500 × g for 10 min to pellet beads. Spin plates at 1500 × g for 10 min to pellet beads. 31.While plates are in centrifuge, prepare THP-1 cells. Count cell concentration and suspend cells to a concentration of 1 × 105 cells/mL. While plates are in centrifuge, prepare THP-1 cells. Count cell concentration and suspend cells to a concentration of 1 × 105 cells/mL. 32.Carefully remove supernatant from plates. Resuspend beads in 200 μL of cells. Carefully remove supernatant from plates. Resuspend beads in 200 μL of cells. 33.Incubate at 37°C for 18 h. Incubate at 37°C for 18 h. 34.After incubation, spin plates at 300 × g for 5 min. After incubation, spin plates at 300 × g for 5 min. 35.Remove 100 μL supernatant from wells. Add 100 μL of 4% paraformaldehyde (PFA) to wells and resuspend cells using pipettor. Remove 100 μL supernatant from wells. Add 100 μL of 4% paraformaldehyde (PFA) to wells and resuspend cells using pipettor. 36.Protect plate from light and incubate at room temperature for 15 min. Protect plate from light and incubate at room temperature for 15 min. 37.Spin plates at 300 × g for 5 min. Spin plates at 300 × g for 5 min. 38.Carefully remove all supernatant from cells. Resuspend cells in 200 μL ADCP Assay buffer. Read plate in flow cytometer analyzing percentage of FITC+ cells. Carefully remove all supernatant from cells. Resuspend cells in 200 μL ADCP Assay buffer. Read plate in flow cytometer analyzing percentage of FITC+ cells. Note: Plates can be read immediately or stored at +4°C for up to one week before reading. Expected outcomes This two-stage assay will allow to obtain two important parameters: concentration of antigen-specific IgG and Phagocytic score that reflects intrinsic differences in antigen-specific IgG between samples. Because concentration of antigen-specific IgG is the major contributing factor to ADCP assay readout, high concentration can mask poor ability of IgG to induce cellular phagocytosis leading to misinterpretation of ADCP assay data. Post-assay normalization by IgG concentration and/or titer might not be feasible due to different dynamic range of binding and ADCP assays. Therefore, equilibration of different samples by concentration of antigen-specific IgG prior to ADCP and other effector function assays is critical to reveal differences in ADCP between samples that are due to difference in IgG glycosylation, epitope specificity and breadth or other IgG intrinsic factors that affect interaction between IgG and Fcγ receptors on phagocytic cells. This approach will be especially useful for longitudinal analysis across patients and cohorts involving severe infections and/or vaccination with mRNA-based vaccines that can elicit very high antibody levels. Limitations While this protocol can provide an increased robustness and completeness to data collection, a limitation of this protocol is the timing. Adding an additional step of IgG concentration measurement decreases sample throughput. However, both the MBAA and ADCP assays can be automated and run in high throughput setting thus allowing stepwise sample processing. Troubleshooting Problem 1 Variability in MFI readout between ADCP experiments (Step 37). Potential solution •Keep THP-1 cell line at consistent cell concentration during culturing. Allowing cells to grow to high concentrations can lead to loss of cell surface marker expression.•Keep NeutrAvidin beads protected from light as much as possible to prevent photobleaching.•Internal quality controls such serum samples with high, medium and low phagocytic score should be included in each assay to directly compare changes in MFI. Including control mAb can also be considered. •Keep THP-1 cell line at consistent cell concentration during culturing. Allowing cells to grow to high concentrations can lead to loss of cell surface marker expression. Keep THP-1 cell line at consistent cell concentration during culturing. Allowing cells to grow to high concentrations can lead to loss of cell surface marker expression. •Keep NeutrAvidin beads protected from light as much as possible to prevent photobleaching. Keep NeutrAvidin beads protected from light as much as possible to prevent photobleaching. •Internal quality controls such serum samples with high, medium and low phagocytic score should be included in each assay to directly compare changes in MFI. Including control mAb can also be considered. Internal quality controls such serum samples with high, medium and low phagocytic score should be included in each assay to directly compare changes in MFI. Including control mAb can also be considered. Problem 2 Low MFI values from MBAA or ADCP assay (Steps 20 and 37). Potential solution •Both the MBAA and ADCP assays use light sensitive reagents. Plates should be protected from light as much as possible during experiments.•Internal quality controls with established levels of IgG and phagocytic score should be included into each experiment to allow standardization and inter-assay comparisons. •Both the MBAA and ADCP assays use light sensitive reagents. Plates should be protected from light as much as possible during experiments. Both the MBAA and ADCP assays use light sensitive reagents. Plates should be protected from light as much as possible during experiments. •Internal quality controls with established levels of IgG and phagocytic score should be included into each experiment to allow standardization and inter-assay comparisons. Internal quality controls with established levels of IgG and phagocytic score should be included into each experiment to allow standardization and inter-assay comparisons. Resource availability Lead contact Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Anton Sholukh (asholukh@fredhutch.org). Technical contact Inquiries specific to preparations and methods of this protocol should be directed to and will be fulfilled by the technical contact, Russell St. Germain (rstgerma@fredhutch.org). Materials availability This study did not generate new unique reagents. Data and code availability Original/source data are available in St. Germain et al.1 Acknowledgments We thank Drs. E.S. Ford and A. Fiore-Gartland for assistance with data processing and Drs. Stamatatos and Strong for SARS-CoV-2 spike and RBD proteins. We are grateful to Drs. McLaughlin, Doll, Wald, and Koelle and Mr. McLaughlin for the help in collecting study samples. This work was supported by A.M.S. internal Fred Hutch funds. Author contributions Conceptualization, R.S.G. and A.M.S.; methodology, R.S.G. and A.M.S.; formal analysis, R.S.G. and A.M.S.; investigation, R.S.G. and A.M.S.; resources, A.M.S.; data curation, R.S.G. and A.M.S.; writing – original draft, R.S.G.; writing – review and editing, R.S.G. and A.M.S.; visualization, R.S.G. and A.M.S.; supervision, A.M.S. Declaration of interests The authors declare no competing interests.